JCB, Volume 11, Number 3, 2005 Editorial Vol.11 No. 3 (2005) Editorial: Is the UK NHS a good place to do clinical trials? Jan Steiner   Commentary Vol.11 No. 3 (2005) Introduction to the debate: How much regulation do we want or need? Derek Burke We in Britain have seen lots of headlines about over-regulation; for example, one headline reported Europe's top motor industries bosses telling the President of the Eu Article Vol.11 No. 3 (2005) NGO war on biotechnology Henry I Miller Discussions of the risks and benefits of recombinant DNA technology, or 'genetic modification' (GM), should occur within the context of experience with older, 'conventi Article Vol.11 No. 3 (2005) Plant biotechnology, the regulator and the consumer Janet Bainbridge The use of genetic modification (GM) technologies to modify food crops provides one of the most hotly debated and often discussed applications of science. As the scienc Article Vol.11 No. 3 (2005) The latest orphan drug designations and the Commission Communication on Regulation (EC) 141/2000 Rashmi R Shah The implementation of Community Regulation on orphan medicinal products in the European Union in April 2000 has resulted in a deluge of applications for designation of Article Vol.11 No. 3 (2005) Corporate development in biotechnology in 2005 Alan Williams In 1998 the author produced two papers which argued that consolidation was a necessary activity for biotechnology companies to consider more. Three years later a furthe Article Vol.11 No. 3 (2005) Distribution of data and unique material resources made with NIH funding Mark L Rohrbaugh The research community, particularly in academic and public sector institutions, recognises that scientists have an obligation to publish the results of their research Article Vol.11 No. 3 (2005) Amgen v TKT: Assessment of inventive concept is crucial for assessing infringement of biotechnology patents William Cook In a landmark decision, the House of Lords in Kirin Amgen v Hoechst & TKT has confirmed the correct approach of proper construction of patent claims, as int Article Vol.11 No. 3 (2005) The quest for generic biotechnology pharmaceuticals in the USA Thomas J Kowalski As patent protection expires on the first generation of biotechnology products, such as human growth hormone and erythropoietin, there is an impetus for the development Article Vol.11 No. 3 (2005) The DNA/RNA market to 2010 Mark Belsey The DNA/RNA market is currently at an early stage of development, with only two marketed products that together generated an estimated US$30m in 2004. The launch of Pfi Legal and Regulatory Updates Vol.11 No. 3 (2005) Legal and regulatory update John Wilkinson Cambridge Antibody Technology (CAT) won its High Court battle against healthcare company Abbott over the level of royalties due on sales of the potential blockbuster dr Legal and Regulatory Updates Vol.11 No. 3 (2005) Financial accounts reports Colin Aaronson Serono International SA is one of the world's largest biotechnology companies with sales in 2004 of almost US$2.5bn made in over 90 countries. The company presently has
